What is the equivalent dose of alogliptin (Dipeptidyl peptidase-4 (DPP-4) inhibitor) for a patient currently taking sitagliptin (Januvia) 100 mg for type 2 diabetes mellitus?

DPP-4 Inhibitor Dose Conversion: Sitagliptin to Alogliptin

For a patient taking sitagliptin 100 mg daily, switch to alogliptin 25 mg once daily. This is the standard equivalent dose conversion between these two DPP-4 inhibitors, as both represent the full therapeutic doses within their respective class 1.

Dose Equivalency Rationale

• Sitagliptin 100 mg once daily is therapeutically equivalent to alogliptin 25 mg once daily 1, 2
• Both doses provide similar HbA1c reductions of approximately 0.4-0.9% and comparable DPP-4 inhibition profiles 1, 3
• The American Diabetes Association recognizes alogliptin as an equivalent medication to sitagliptin (Januvia) for enhancing insulin secretion and reducing glucagon in a glucose-dependent manner 1

Critical Renal Function Considerations

Before making this switch, you must assess the patient's renal function, as alogliptin requires dose adjustment in renal impairment while sitagliptin may already be dose-adjusted 1:

Alogliptin Dosing by eGFR 1:

• eGFR >60 mL/min/1.73 m²: Alogliptin 25 mg daily (full dose)
• eGFR 30-60 mL/min/1.73 m²: Alogliptin 12.5 mg daily (half dose)
• eGFR <30 mL/min/1.73 m²: Alogliptin 6.25 mg daily (quarter dose)

Sitagliptin Dosing by eGFR 1, 4:

• eGFR ≥45 mL/min/1.73 m²: Sitagliptin 100 mg daily
• eGFR 30-44 mL/min/1.73 m²: Sitagliptin 50 mg daily
• eGFR <30 mL/min/1.73 m²: Sitagliptin 25 mg daily

Cardiovascular Safety Warning

Avoid alogliptin in patients with heart failure risk or established heart failure, as alogliptin has been associated with increased heart failure hospitalization in cardiovascular outcomes trials 1. The FDA issued a specific warning about this risk 1.

• If the patient has heart failure or significant cardiac disease: Consider switching to linagliptin 5 mg daily instead, which has neutral heart failure risk 1
• If the patient has established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease with albuminuria: The American College of Cardiology recommends prioritizing SGLT2 inhibitors or GLP-1 receptor agonists over any DPP-4 inhibitor due to proven cardiovascular and renal benefits 1

Clinical Algorithm for Switching

1. Check eGFR immediately 1
2. Assess for heart failure history or risk factors 1
3. If eGFR >60 mL/min/1.73 m² AND no heart failure concerns: Switch to alogliptin 25 mg daily 1
4. If eGFR 30-60 mL/min/1.73 m²: Switch to alogliptin 12.5 mg daily 1
5. If eGFR <30 mL/min/1.73 m²: Switch to alogliptin 6.25 mg daily 1
6. If heart failure present or high risk: Consider linagliptin 5 mg daily instead (no dose adjustment needed for any renal function) 1

Important Caveats

• Monitor for hypoglycemia if the patient is also taking sulfonylureas or insulin, as the addition of any DPP-4 inhibitor to sulfonylurea therapy increases hypoglycemia risk by approximately 50% 1
• Reassess HbA1c within 3 months of the switch to ensure continued glycemic control 1
• Both medications are weight-neutral with minimal hypoglycemia risk when used as monotherapy 1
• Cardiovascular outcomes trials for both sitagliptin and alogliptin showed cardiovascular safety but no cardiovascular benefit, unlike SGLT2 inhibitors and GLP-1 receptor agonists 5, 1